Inari Medical, Inc. (NASDAQ:NARI) Receives $61.80 Average PT from Analysts

Shares of Inari Medical, Inc. (NASDAQ:NARI) have been assigned a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $68.00.

Several equities analysts have weighed in on NARI shares. Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Oppenheimer started coverage on Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price objective for the company. BTIG Research reaffirmed a “neutral” rating on shares of Inari Medical in a research report on Wednesday. Piper Sandler increased their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 7th. Finally, Truist Financial lifted their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, December 18th.

Inari Medical Trading Down 0.0 %

Shares of NASDAQ NARI opened at $79.29 on Tuesday. Inari Medical has a 12-month low of $36.73 and a 12-month high of $79.69. The company has a 50-day moving average of $54.72 and a 200 day moving average of $49.60. The stock has a market cap of $4.64 billion, a PE ratio of -58.73 and a beta of 0.97.

Insider Activity at Inari Medical

In other news, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the completion of the sale, the director now owns 238,987 shares of the company’s stock, valued at $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares in the company, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 406,000 shares of company stock valued at $22,621,870 over the last quarter. Insiders own 10.60% of the company’s stock.

Hedge Funds Weigh In On Inari Medical

Large investors have recently bought and sold shares of the stock. Arizona State Retirement System increased its position in Inari Medical by 2.5% during the 2nd quarter. Arizona State Retirement System now owns 14,602 shares of the company’s stock worth $703,000 after purchasing an additional 358 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Inari Medical by 67.2% in the 3rd quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after buying an additional 473 shares in the last quarter. KBC Group NV lifted its stake in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after purchasing an additional 522 shares in the last quarter. Finally, Cerity Partners LLC grew its position in shares of Inari Medical by 2.8% during the third quarter. Cerity Partners LLC now owns 24,056 shares of the company’s stock worth $992,000 after buying an additional 652 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.